Nektar Therapeutics Newsroom

Nektar Therapeutics(NKTR.US) 10% Shareholder Sells US$99,629.6 in Common Stock

$Nektar Therapeutics(NKTR.US)$ 10% Shareholder Deep Track Capital, LP sold 56,000 shares of common stock on May 10, 2024 at an average price of $1.7791 for a total value of $99,629.6. This transaction

moomoo NewsMay 13 17:19 ET

Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview

Yahoo FinanceMay 10 15:14 ET

Nektar Therapeutics | 10-Q: Quarterly report

Futu NewsMay 10 14:13 ET · Announcements

Express News | Nektar Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results

BenzingaMay 10 12:48 ET

Q1 2024 Nektar Therapeutics Earnings Call

Yahoo FinanceMay 10 10:35 ET

Earnings Call Summary | Nektar Therapeutics(NKTR.US) Q1 2024 Earnings Conference

The following is a summary of the Nektar Therapeutics, Inc. (NKTR) Q1 2024 Earnings Call Transcript:Financial Performance:Nektar ended Q1 with a cash balance of $326 million and anticipates to close 2

moomoo AIMay 10 06:26 ET · Conference Call

Nektar Therapeutics, Inc. (NKTR) Q1 2024 Earnings Call Transcript

Nektar Therapeutics, Inc. (NKTR) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 9 22:40 ET

Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q1 Revenue $21.6M, Vs. Street Est of $15.3M

04:39 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q1 Revenue $21.6M, vs. Street Est of $15.3M

MT NewswiresMay 9 16:39 ET

Nektar Therapeutics Q1 Loss Drops In Line With Estimates

RTTNewsMay 9 16:19 ET

Express News | Nektar Therapeutics Q1 Product Sales USD 6.034 Million

ReutersMay 9 16:15 ET

Express News | Nektar Therapeutics Q1 EPS USD -0.19

ReutersMay 9 16:15 ET

Express News | Nektar Therapeutics Q1 Net Income USD -36.802 Million

ReutersMay 9 16:15 ET

Express News | Nektar Therapeutics Q1 Income From Operations USD -35.427 Million

ReutersMay 9 16:15 ET

Nektar Therapeutics Reports First Quarter 2024 Financial Results

SAN FRANCISCO, May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024. Cash and investments in marketable securi

NektarMay 9 00:00 ET

12 Health Care Stocks Moving In Tuesday's After-Market Session

GainersClover Health Investments (NASDAQ:CLOV) shares increased by 14.9% to $0.85 during Tuesday's after-market session. The market value of their outstanding shares is at $421.4 million. The company'

BenzingaMay 7 16:31 ET

Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets

SAN FRANCISCO, May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based fin

NektarMay 2 00:00 ET

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

GainersCyclacel Pharmaceuticals (NASDAQ:CYCC) stock moved upwards by 50.0% to $2.04 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. GeneDx Hldgs (NASDAQ:WGS) shar

BenzingaApr 30 08:06 ET

NK Cell Therapies Pipeline Report 2024: Insights on 80+ Companies and 100+ Pipeline Drugs, Including ALECSAT (CytoVac), NKTR-214/Bempegaldesleukin (Nektar Therapeutics), and Monalizumab (Innate Pharma)

Yahoo FinanceApr 26 04:12 ET

Express News | Nektar Therapeutics:Received Letter From Nasdaq Notifying Co It Regained Compliance With Minimum Bid Price Requirement for Continued Listing on Nasdaq

Moomoo 24/7Apr 17 17:06 ET

Express News | Nektar Therapeutics Shares Hit Session Low With Volume Pickup, Last Down 8.4% at $1.53

Moomoo 24/7Apr 15 14:59 ET